DOCSLIB.ORG

EHIM Cares Custom Me Too Closed Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EHIM Cares Custom Me Too Closed Formulary EHIM Cares Custom Me Too Closed Formulary 26711 Northwestern Highway, Suite 400 :: Southfield, MI 48033-2154 :: 800-311-3446 :: 248-948-9900 :: www.ehimrx.com EHIM Cares Custom Formulary is a well-designed, evidenced- currently available and less costly therapies. This listing is based formulary that optimizes patient outcomes by ensuring revised periodically as new medications and new prescribing that patients receive the most effective and safe therapy. All information becomes available. If you are utilizing an Excluded medications are reviewed by EHIM Pharmacy & Therapeutics or Non-Preferred medication, you may want to speak with Committee for clinical efficacy, safety and cost savings for your physician to determine if there is an alternative therapy formulary consideration. that provides the same therapeutic efficacy, but is available at a lower cost to you. This document may be shared with your This list of medications is a guide which includes preferred physician to evaluate potential preferred therapy options. medications within select therapeutic classes that demonstrate the greatest value to you and your Employer. For additional benefit coverage information, please check Medications are excluded from formulary coverage if they your benefit plan documents or feel free to contact the EHIM fail to demonstrate a clinical or safety advantage over Pharmacy Call Center at 800-311-3446. Frequently Asked Questions About Generic Medications What is a generic drug? Are generics really the same as the brand name? A generic drug is a lower cost version of a brand-name Yes. Generic drugs have the same medicine as the brand- medication. They are just as safe and effective as the brand name, and the FDA will not approve them unless they are name, but they are more affordable. just as safe and effective as the brand-name drug. There are a few special medical conditions where a generic drug might How are generic drugs different from brand name drugs? have a small difference in how it works, but that is very rare. The biggest difference between a generic and brand name Do generic drugs cause more side effects than brand-name drug is the price. Most generics cost 70-90% less than the drugs? brand name version. Generic drugs may also have a different No. Brand-name drugs and a generic drug have the same shape, color or package. But these differences only affect rates of side effects. Each medication can affect each person how the medicine looks, not how it works. in a different way. If your medicine has side effects that you are worried about, call your doctor. • All MULTISOURCE medications (DAW) (brand name • Some medications may require an approved Prior medications that have an EXACT generic equivalent) are Authorization before being covered subject to the Non-Preferred copay (Not All MULTISOURCE medications are listed on this Formulary or may be covered) • Some medications may be applicable to a Quantity Limitation • All forms (oral, liquid, topical…) and dosages (DR, ER, LA, XR….) of the medications listed are classified as Non- • Not all medications on this formulary may be covered by Preferred your plan • This formulary is subject to change at any time without notice ehimrx.com EHIM Cares Custom Me Too Closed Formulary 26711 Northwestern Highway, Suite 400 :: Southfield, MI 48033-2154 :: 800-311-3446 :: 248-948-9900 :: www.ehimrx.com Non-Preferred medications are highlighted. Preferred generic medications are WHITE. Any medication in the 1st Tier can be interchanged for any of the medications in the 4th or 3rd Tier. This list is intended to be a guide. Not all medications listed on this formulary may be covered by your plan. derreferP-noN derreferP Excluded derreferP-noN derreferP Excluded yapoC yapoC yapoC yapoC Alzheimer’s/Dementia Analgesics/Narcotics Con’t Namenda XR donepezil Ryzolt (tramadol) tramadol/APAP (memantine) (Ultracet) Namzaric (donepezil/ memantine Synalgos memantine) (dihydrocodeine, APAP, Analgesics/Narcotics caffeine) Aleveer (capsaicin) Abstral (fentanyl) buprenorphine/naloxone Trezix (dihydrocodeine, SL (Suboxone) caffeine, APAP) Allzital (butalbital/ Embeda (morphine buprenorphine patch Troxyca ER acetaminophen) naltrexone) (Butrans) (oxycodone, Avinza (morphine) Fentora (fentanyl codeine naltrexone) buccal) Ultram ER (tramadol) Belbuca Hysingla ER codeine/APAP (buprenorphine) (hydrocodone) Xartemis XR Bunavail Lazanda (fentanyl) fentanyl patch (oxycodone/ (buprenorphine/ (Duragesic) acetaminophen) naloxone) Zydone (hydrocodone, Butrans Nucynta, Nucynta ER hydrocodone/APAP APAP) (buprenorphine) (tapentadol) (Lortab, Norco, Vicodin, Zubsolv etc) (buprenorphine/ Cassipa Obredon hydrocodone/ibuprofen naloxone) (buprenorphine/ (hydrocodone, (Vicoprofen) Androgens/Hypogonadism naloxone) guaifenesin) Xyosted (testosterone Androderm testosterone cypionate inj Conzip (tramadol) Onsolis (fentanyl hydromorphone enanthate) Injection (testosterone) buccal) (Dilaudid) Androgel Elenza (capsaicin) Opana ER hydromorphone XR (testosterone) (oxymorphone) (Exalgo) Android Flowtuss (hydrocodone, Oxycontin (oxycodone) levorphenol (Levo (methyltestosterone) guaifenesin) Dromoran) Androxy Hycofenix Subsys (fentanyl) methadone (fluoxymesterone) (hydrocodone, pse, Aveed (testosterone guaifenesin) undecanote) Hydrocodone Targiniq ER morphine Axiron (testosterone) Bitartrate, Guaifenesin (oxycodone/naloxone) Tablets Danocrine (danazol) Morphabond Viberzi (eluxadoline) morphine ER (MS Contin, Delatestryl (morphine sulfate) Oramorph) (testosterone Oxaydo (oxycodone) Vicodin (hydrocodone/ oxycodone (OxyIR) enanthate) Inj acetaminophen) Depo-Testosterone Oxecta (oxycodone IR) Zohydro ER oxycodone/APAP (testosterone cyp) Inj (hydrocodone) (Percocet) Halotestin Qroxin (capsaicin) oxycodone/ibuprofen (fluoxymesterone) (Combunox) Methitest Renovo (capsaicin) oxymorphone IR (Opana) (methyltestosterone) Roxybond (oxycodone) tramadol (Ultram) Methyltestosterone Oral Tablets (Testred) Rybix ODT (tramadol) ehimrx.com EHIM Cares Custom Me Too Closed Formulary 26711 Northwestern Highway, Suite 400 :: Southfield, MI 48033-2154 :: 800-311-3446 :: 248-948-9900 :: www.ehimrx.com Non-Preferred medications are highlighted. Preferred generic medications are WHITE. Any medication in the 1st Tier can be interchanged for any of the medications in the 4th or 3rd Tier. This list is intended to be a guide. Not all medications listed on this formulary may be covered by your plan. derreferP-noN derreferP derreferP-noN derreferP Excluded yapoC yapoC Excluded yapoC yapoC Androgens/Hypogonadism Con’t Anticoagulants Natesto (testosterone) Eliquis (apixaban) warfarin Nasal Pradaxa (dabigatran) Oxandrin Savaysa (edoxaban) (oxandrolone) Xarelto (rivaroxaban) Striant XR Anticonvulsants/Seizures (testosterone) Elepsia XR Aptiom carbamazepine Testim (testosterone) (levetiracetam) (eslicarbazepine) (Tegretol) Testoprel Gralise (gabapentin) Briviact (brivacetam) carbamazepine XR (testosterone) (Tegretol XR) Testred Horizant (gabapentin) Carbatrol clonazepam (Klonopin) (methyltestosterone) (carbamazepine) Virilon Keppra XR Diastat Rectal Delivery divalproex (Depakote) (methyltestosterone) (levetiracetam) System (diazepam) Vogelxo (testosterone) Lamictal XR Dilantin (phenytoin)* divalproex ER (Depakote Anti Arthritics (lamotrigine) ER) Cambia (diclofenac) Flector Patch celecoxib (Celebrex) Lyrica CR (pregabalin) Equetro ethosuximide (Zarontin) Packets (diclofenac) (carbamazepine) Consensi (amlodipine, Indocin (indomethacin) diclofenac (Cataflam, Onfi (clobazam) Felbatol (felbamate) felbamate (Felbatol) celecoxib) supp Voltaren, Voltaren XR) Oxtellar XR Fycompa (perampanel) gabapentin (Neurontin) Duexis (ibuprofen, Siprix Nasal Spray diclofenac/misoprostol (oxcarbazepine) famotidine) (ketorolac) (Arthrotec) Qudexy XR Gabitril (tiagabine) lacosamide (Vimpat) Durlaza (aspirin) diclofenac 1% topical (topiramate) (Voltaren Gel) Spritam Lyrica (pregabalin) lamotrigine (Lamictal) Licart (diclofenac) diclofenac 1.5% topical (levetiracetam) (Pennsaid) Stavzor (valproic acid) Mebaral lamotrigine XR (Lamictal Nalfon (fenoprofen) etodolac (Lodine, Lodine (mephobarbital) XR) XL) Tegretol XR Nayzilam Nasal levetiracetam (Keppra) Naprelan (naproxen) ibuprofen (Motrin) (carbamazepine) (midazolam) Nexcede (ketoprofen) indomethacin (Indocin) Trokendi XR Peganone (ethotoin) oxcarbazepine (Trileptal) Film (topiramate) Pennsaid Topical ketoprofen (Orudis, Phenytek (phenytoin)* phenobarbital Solution (diclofenac) Oruvail) Potiga (ezogabine) phenytoin (Dilantin) Prevacid NapraPac lidocaine topical primidone (Mysoline) (naproxen, (Lidoderm) rufinamide (Banzel) lansoprazole) tiagabine (Gabitril) Tivorbex meloxicam (Mobic) (indomethacin) topiramate (Topamax) Vimovo (naproxen nabumetone (Relafen) valproate, valproic acid esomeprazole) zonisamide (Zonegran) Vivlodex (meloxicam) naproxen (Naproxen) Zipsor (diclofenac) naproxen DS (Anaprox DS) Zorvolex (diclofenac) oxaprozin (Daypro) piroxicam (Feldene) sulindac (Clinoril) ehimrx.com EHIM Cares Custom Me Too Closed Formulary 26711 Northwestern Highway, Suite 400 :: Southfield, MI 48033-2154 :: 800-311-3446 :: 248-948-9900 :: www.ehimrx.com Non-Preferred medications are highlighted. Preferred generic medications are WHITE. Any medication in the 1st Tier can be interchanged for any of the medications in the 4th or 3rd Tier. This list is intended to be a guide. Not all medications listed on this formulary may be covered by your plan. derreferP-noN derreferP Excluded derreferP-noN derreferP Excluded yapoC yapoC yapoC yapoC Antidiabetics Antihypertensives/Angiotension
Load more

Recommended publications
  • Totalcare Medicaid 2017 Q2 GB
    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
    [Show full text]
  • Pharmacology of Ophthalmic Agents
    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub
    US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Accommodation of Three Regimens of Topical Dapiprazole Br J Ophthalmol: First Published As 10.1136/Bjo.79.6.544 on 1 June 1995
    544 British Journal of Ophthalmology 1995; 79: 544-548 Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole Br J Ophthalmol: first published as 10.1136/bjo.79.6.544 on 1 June 1995. Downloaded from Charles S Wilcox, Jon F Heiser, Anna Mae Crowder, Nancy J Wassom, Barbara B Katz, Jacqueline L Dale Abstract mydriasis induced by sympathomimetic Background-Patients who have their agents, such as phenylephrine, and parasympa- pupils dilated for an eye examination tra- tholytics, such as tropicamide, dapiprazole also ditionally have to wait several hours shows a beneficial effect on loss of accommo- before their pupils return to normal size dation,1 although the exact mechanism for its and their blurred vision (caused by paral- effect on accommodation is unknown. In most ysis of accommodation) resolves. Earlier patients, reversal of mydriasis and improve- studies with dapiprazole have demon- ment in accommodation begin within 15 strated an accelerated reversal of dilata- minutes of administration of the drug. tion. Since its introduction, dapiprazole has been Methods-Three regimens of dapiprazole used in a 2+2 regimen, two drops followed by were studied to determine the effects on two more drops 5 minutes later. In clinical pupil diameter and accommodation after practice, returning to dose the patient for a mydriasis produced by 2.5% phenyl- second time in 5 minutes can sometimes be ephrine and 0.5% tropicamide. Test troublesome for both the ophthalmologist and regimens included one drop and 1 + 1 the patient. After a review of the literature on drop regimens, compared with a 2 +2 drop dapiprazole, Doughty and Lyle2 suggested that reference regimen.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • PAPER SPRAY MASS SPECTROMETRY for RAPID DRUG SCREENING by Rachel Jett
    PAPER SPRAY MASS SPECTROMETRY FOR RAPID DRUG SCREENING by Rachel Jett A Thesis Submitted to the Faculty of Purdue University In Partial Fulfillment of the Requirements for the degree of Master of Science Department of Chemistry Indianapolis, Indiana August 2017 ii THE PURDUE UNIVERSITY GRADUATE SCHOOL STATEMENT OF COMMITTEE APPROVAL Dr. Nick Manicke, Chair Department of Chemistry and Chemical Biology Dr. John Goodpaster Department of Chemistry and Chemical Biology Dr. Michael McLeish Department of Chemistry and Chemical Biology Approved by: Dr. Eric C. Long Head of the Graduate Program iii To the Creator- Who places the mysteries of the world before us and the curiosities of the mind within us iv ACKNOWLEDGMENTS This project would not have been possible without the input, support, and feedback of the Manicke and Goodpaster Groups: Nick, Chengsen, Brandon, Greta, Josiah, Grace, John, Dana, Will, Jordan, Clinton Thank you. v TABLE OF CONTENTS LIST OF TABLES ........................................................................................................... viii LIST OF FIGURES ............................................................................................................ x LIST OF ABBREVIATIONS .......................................................................................... xiv ABSTRACT ................................................................................................................. xv CHAPTER 1: BACKGROUND ........................................................................................
    [Show full text]